BACKGROUND: Men undergoing treatment of clinically localised prostate cancer may experience a number of treatment-related complications, which affect their quality of life.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS: On the basis of population-based retrospective cohort of men undergoing surgery, with or without subsequent radiotherapy, or radiotherapy alone for prostate cancer in Ontario, Canada, we measured the incidence of treatment-related complications using administrative and billing data.
RESULTS: Of 36 984 patients, 15 870 (42.9%) underwent surgery alone, 4519 (12.2%) underwent surgery followed by radiotherapy, and 16 595 (44.9%) underwent radiotherapy alone. For all end points except urologic procedures, the 5-year cumulative incidence rates were lowest in the surgery only group and highest in the radiotherapy only group. Intermediary rates were seen in the surgery followed by radiotherapy group, except for urologic procedures where rates were the highest in this group. Although age and comorbidity were important predictors, radiotherapy as the primary treatment modality was associated with higher rates for all complications (adjusted hazard ratios 1.6-4.7, P=0.002 to < 0.0001).
CONCLUSIONS: In patients treated for prostate cancer, radiation after surgery increases the rate of complications compared with surgery alone, though these rates remain lower than patients treated with radiation alone. This information may inform patient and physician decision making in the treatment of prostate cancer.
Wallis CJ, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, Kulkarni GS, Lee Y, Kodama RT, Narod SA, Nam RK. Are you the author?
Division of Urology, Toronto, ON, Canada M4N3M5; Department of Radiation Oncology, Toronto, ON, Canada M4N3M5; Institute of Evaluative Clinical Sciences, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, 2075 Bayview Ave., Toronto, ON, Canada M4N3M5; Division of Urology, University Health Network, University of Toronto, 610 University Ave., Toronto, ON, Canada M5G2M9; Department of Medicine, St Michael's Hospital, University of Toronto, 30 Bond St, Toronto, ON, Canada M5B1W8; Department of Public Health Sciences, University of Toronto, 790 Bay St, Toronto, ON, Canada M5G1N8.
Reference: Br J Cancer. 2015 Mar 17;112(6):977-82.